Cargando…

A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe

PURPOSE: This review aims to describe the sampling methodology used in studies assessing effectiveness of risk minimisation measures (RMMs) in the European Union. METHODS: The European Union electronic Register of Post‐Authorization Studies (EU PAS Register) was searched to identify studies that ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Jouaville, Laurence Sophie, Paul, Tulika, Almas, Mariana Ferreira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453956/
https://www.ncbi.nlm.nih.gov/pubmed/34092001
http://dx.doi.org/10.1002/pds.5301
_version_ 1784570388585381888
author Jouaville, Laurence Sophie
Paul, Tulika
Almas, Mariana Ferreira
author_facet Jouaville, Laurence Sophie
Paul, Tulika
Almas, Mariana Ferreira
author_sort Jouaville, Laurence Sophie
collection PubMed
description PURPOSE: This review aims to describe the sampling methodology used in studies assessing effectiveness of risk minimisation measures (RMMs) in the European Union. METHODS: The European Union electronic Register of Post‐Authorization Studies (EU PAS Register) was searched to identify studies that assessed the effectiveness of RMMs and recruited a target population of healthcare professionals (HCPs), sites or patients. Studies with both protocol and report were included and data was extracted from these documents to describe study characteristics and variables involved in the sampling methodology. RESULTS: Out of 1092 studies finalised between June 2017 and May 2019, 17 studies were eligible for review. Thirteen were surveys, three chart reviews and one combined both methodologies. All the 17 studies recruited HCPs/sites and 8 of them also recruited patients. The most common rationale for country sampling was market uptake (10/17), while for HCP/site sampling, it was representativeness of the prescribing practices (14/17). Only a minority of the studies (4/17) provided supporting evidence to inform this theoretical framework. HCP/site sampling frames were mainly network of physicians (5/17) or HCP databases (5/17), with only one study providing a detailed description of the sampling frame. HCPs were selected mainly using probabilistic sampling (10/17) and patients using non‐probabilistic sampling (6/8). Only a few studies compared participating with non‐participating HCPs/sites (5/17) and patients (3/8). Eight studies reported that their results were generalisable. CONCLUSIONS: Overall, the study documents provided insufficient details to understand the rationale behind the sampling decisions. More standardisation and guidance in reporting the sampling strategy and operational considerations applicable to these types of studies would support transparency and facilitate the evaluation of representativeness of the study results.
format Online
Article
Text
id pubmed-8453956
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-84539562021-09-27 A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe Jouaville, Laurence Sophie Paul, Tulika Almas, Mariana Ferreira Pharmacoepidemiol Drug Saf Reviews PURPOSE: This review aims to describe the sampling methodology used in studies assessing effectiveness of risk minimisation measures (RMMs) in the European Union. METHODS: The European Union electronic Register of Post‐Authorization Studies (EU PAS Register) was searched to identify studies that assessed the effectiveness of RMMs and recruited a target population of healthcare professionals (HCPs), sites or patients. Studies with both protocol and report were included and data was extracted from these documents to describe study characteristics and variables involved in the sampling methodology. RESULTS: Out of 1092 studies finalised between June 2017 and May 2019, 17 studies were eligible for review. Thirteen were surveys, three chart reviews and one combined both methodologies. All the 17 studies recruited HCPs/sites and 8 of them also recruited patients. The most common rationale for country sampling was market uptake (10/17), while for HCP/site sampling, it was representativeness of the prescribing practices (14/17). Only a minority of the studies (4/17) provided supporting evidence to inform this theoretical framework. HCP/site sampling frames were mainly network of physicians (5/17) or HCP databases (5/17), with only one study providing a detailed description of the sampling frame. HCPs were selected mainly using probabilistic sampling (10/17) and patients using non‐probabilistic sampling (6/8). Only a few studies compared participating with non‐participating HCPs/sites (5/17) and patients (3/8). Eight studies reported that their results were generalisable. CONCLUSIONS: Overall, the study documents provided insufficient details to understand the rationale behind the sampling decisions. More standardisation and guidance in reporting the sampling strategy and operational considerations applicable to these types of studies would support transparency and facilitate the evaluation of representativeness of the study results. John Wiley & Sons, Inc. 2021-06-24 2021-09 /pmc/articles/PMC8453956/ /pubmed/34092001 http://dx.doi.org/10.1002/pds.5301 Text en © 2021 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Jouaville, Laurence Sophie
Paul, Tulika
Almas, Mariana Ferreira
A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe
title A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe
title_full A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe
title_fullStr A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe
title_full_unstemmed A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe
title_short A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe
title_sort review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in europe
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453956/
https://www.ncbi.nlm.nih.gov/pubmed/34092001
http://dx.doi.org/10.1002/pds.5301
work_keys_str_mv AT jouavillelaurencesophie areviewofthesamplingmethodologyusedinstudiesevaluatingtheeffectivenessofriskminimisationmeasuresineurope
AT paultulika areviewofthesamplingmethodologyusedinstudiesevaluatingtheeffectivenessofriskminimisationmeasuresineurope
AT almasmarianaferreira areviewofthesamplingmethodologyusedinstudiesevaluatingtheeffectivenessofriskminimisationmeasuresineurope
AT jouavillelaurencesophie reviewofthesamplingmethodologyusedinstudiesevaluatingtheeffectivenessofriskminimisationmeasuresineurope
AT paultulika reviewofthesamplingmethodologyusedinstudiesevaluatingtheeffectivenessofriskminimisationmeasuresineurope
AT almasmarianaferreira reviewofthesamplingmethodologyusedinstudiesevaluatingtheeffectivenessofriskminimisationmeasuresineurope